

Divisional of U.S. Serial No. 08/894,327
Atty. Dkt. No.: 02973.00031
Page 2

IN THE CLAIMS:

Please cancel claims 1-22.

Please amend claims 23 and 24 as follows:

23. (AMENDED) A method of treating an individual for a condition selected from the group consisting of exposure to DNA damaging agents, abnormal cell proliferation characteristic of psoriasis, atherosclerosis, cancer, and arterial restenosis, undesirable immune response accompanying rejection of a transplant and an autoimmune disease, comprising administering to the patient a pharmaceutical composition comprising a peptide having at least four sequential amino acids from a negative regulatory region which maps to residues 361-383 (SEQ. ID. No. 12) of p53, said peptide not being a subfragment of human p53, wherein said peptide activates DNA binding of wild-type p53 or a p 53 mutant containing a single amino acid substitution, said mutant selected from the group consisting of p53-ser²³⁹, p53-his²⁷³, p53-gln²⁴⁸, p53-trp²⁸², and p53-cys²⁷³, in a p53 DNA binding assay and a pharmaceutically acceptable carrier.
24. (AMENDED) A method for treating a patient having a tumor expressing a p53 mutant whose ability to bind DNA may be activated by peptides, modified peptides or peptidomimetics corresponding to all or a portion of the negative regulatory region which maps to residues 361-383 of p53, said method comprising administering to said patient a pharmaceutical composition comprising a peptide having at least four sequential amino acids from a negative regulatory region which maps to residues 361-383 (SEQ. ID. No. 12) of p53, said peptide not being a subfragment of human p53, wherein said peptide activates DNA binding of wild-type p53 or a p 53 mutant containing a single amino acid substitution, said mutant selected from the group consisting of p53-ser²³⁹, p53-his²⁷³, p53-gln²⁴⁸, p53-trp²⁸², and p53-cys²⁷³, in a p53 DNA binding assay and a pharmaceutically acceptable carrier.

SEQUENCE LISTING